Optogenetic stimulation of the hippocampal CA1 astrocytes does not significantly affect the expression of AMPA receptors or VGLUT2. by Jae-Hong Kim (124622)

Participants with virologic suppression or failure at week 24. by Tosi M. Mwakyandile (16408705)

Table_5_Desiccation as a Post-maturation Treatment Helps Complete Maturation of Norway Spruce Somatic Embryos: Carbohydrates, Phytohormones and Proteomic Status.xlsx by Kateřina Eliášová (5621759)

image5_Safety and Efficacy of Bromodomain and Extra-Terminal Inhibitors for the Treatment of Hematological Malignancies and Solid Tumors: A Systematic Study of Clinical Trials.jpeg by Yanli Sun (1559716)

“…According to published data, the rates of SD, PD, CR and PR were 27.4%, 37.6%, 3.5%, and 5.7%, respectively, which is not very satisfactory. …”

Socio-demographic and clinical characteristics of HIV-infected treatment-naïve individuals initiating ART. by Tosi M. Mwakyandile (16408705)

Distribution of traffic accidents by age, gender, and seat belt use. by Bayapa Reddy Narapureddy (11875358)

Distribution of Facial bone fractures associated with other body structures injuries. by Bayapa Reddy Narapureddy (11875358)

Consolidated Standards of Reporting Trials flow diagram for participants in the trial. by Tosi M. Mwakyandile (16408705)

Facial traumas considering seat belt use in victims. by Bayapa Reddy Narapureddy (11875358)

I Optimal design for optimization of Axitinib loaded Spanlastics. by Randa Mohammed Zaki (21637175)

ANOVA for I optimal design of Axitinib loaded Spanlastics. by Randa Mohammed Zaki (21637175)

Traffic accident victims by position in the vehicle, gender, and safety equipment. by Bayapa Reddy Narapureddy (11875358)

The kinetic release data of the optimized formula compared to drug suspension. by Randa Mohammed Zaki (21637175)

Composition of different formulations with their responses in I optimal design for optimization of Axitinib loaded Spanlastics. by Randa Mohammed Zaki (21637175)

The composition and validation of the optimized formula with its predicted responses according to I Optimal Design. by Randa Mohammed Zaki (21637175)

Changes in baseline CD4 count through week 12 and week 24 according to the linear regression model. by Tosi M. Mwakyandile (16408705)

Most frequently experienced adverse events among study participants by treatment arms from baseline through week 24. by Tosi M. Mwakyandile (16408705)

Frequency of body traumas associated with facial traumas according to seat belt use. by Bayapa Reddy Narapureddy (11875358)

Distribution of multiple Injuries associated with seat belt use vs Age groups. by Bayapa Reddy Narapureddy (11875358)

Cumulative incidence of mortality and loss to follow-up (LTF) among study participants by treatment arms from baseline through week 24. by Tosi M. Mwakyandile (16408705)